Navigation Links
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
Date:12/7/2008

SAN FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported the Phase I results from a randomized, multi-center, Company-sponsored Phase I/II study of VELCADE, dexamethasone, cyclophosphamide and lenalidomide (VcDCR) in patients with previously untreated multiple myeloma (MM). The preliminary analysis of the safety data showed that the combination of four drugs was generally well tolerated in patients who had received no prior therapies and response rates were encouraging. These data were presented at the 50th Annual Meeting of the American Society of Hematology (ASH), held December 5-9, 2008 in San Francisco, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

This trial, called EVOLUTION(1), builds on positive results from previous studies of VELCADE based combinations in this setting. The presentation reported the first clinical data with the novel four-drug combination. The safety results allow the trial to proceed to Phase II, which will randomize patients to receive VcDR, VcDC or VcDCR.

Results from the 25 patients treated in this trial with VcDCR for a median of four cycles (range: 2-11 cycles), which were presented by Shaji Kumar, M.D., Mayo Clinic, showed:

-- The maximum tolerated dose of cyclophosphamide in the VcDCR regimen was not reached. The recommended doses for the Phase II portion of the trial include 500 mg/m(2) of cyclophosphamide, the highest planned dose, 1.3 mg/m(2) of VELCADE, 40 mg of dexamethasone and 15 mg of lenalidomide.

-- The only two dose-limiting toxicities reported were febrile neutropenia and reactivation of the Herpes Zoster virus infection.

-- The overall rate of serious adverse events (AEs) was 40 percent. The most common treatment-emergent AEs were constipation (64 percent), fatigue
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Based On Naturally Resected tRNA Synthetases , ... subsidiary of aTyr Pharma in Hong Kong, today announced ... naturally occurring, resected human tRNA synthetases. Although tRNA ... machinery found in all organisms, human synthetases have naturally ...
... RICHMOND, Calif., June 29 Sangamo BioSciences, Inc. (Nasdaq: ... research milestone has been achieved in its Research and ... the Roche Group, for the generation of cell lines ... Sangamo,s proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. ...
Cached Medicine Technology:Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3
(Date:7/10/2014)... Emergency Medical Service (EMS) responders felt better prepared to ... tactical training according to a new study in the ... the first study to specifically examine the EMS provider ... a shooter has not yet been neutralized or working ... such as the Columbine High School shooting, the Virginia ...
(Date:7/10/2014)... beverages consumed, even for light-to-moderate drinkers, may improve ... heart disease, lower body mass index (BMI) and ... published in The BMJ and co-led ... University of Pennsylvania. The latest findings call into ... amounts of alcohol (0.6-0.8 fluid ounces/day) may have ...
(Date:7/10/2014)... The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. , ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization. ...
(Date:7/10/2014)... benefits of medical imaging far outweigh the risks when ... with The Right Radiation Dose. However, overuse and misuse ... is leading a collaborative effort to ensure a national ... in the Journal of Patient Safety , calls ... the Intersociety Accreditation Commission, and the Centers for Medicare ...
(Date:7/10/2014)... A research review identifying the clinical indicators most strongly ... the process of developing evidence-based guidelines for concussion diagnosis, ... by Neurosurgery , official journal of ... journal is published by Lippincott Williams & Wilkins ... . , Based on analysis of the best ...
Breaking Medicine News(10 mins):Health News:Active shooter training increases comfort level of emergency responders 2Health News:New study shows drinking alcohol provides no heart health benefit 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3
... Bio-Pharmaceutical,Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer ... use in pharmaceutical,nutraceutical and food production, is pleased to ... month periods ended September 30, 2008. , ... that in the third quarter of 2008, Huifeng has,managed ...
... and TOKYO, Nov. 21 DATATRAK,International, Inc. (Nasdaq: ... company focused,on global eClinical solutions for the clinical ... Japan, NTT DATA Corporation, has placed its first,self-designed ... a Japanese clinical trial. The successful rollout ...
... 21 Vital Images, Inc.,(Nasdaq: VTAL ), ... Toshiba Medical Systems Corporation (Toshiba), have agreed to,renew their ... , As under ... its subsidiaries and distributors in more than 50 nations ...
... Patient Assistance ( www.PatientAssistance.com ) has released initial survey results ... ... Baton Rouge, LA – November 20, ... on diabetes awareness amongst the predominantly uninsured and underinsured visitors ...
... Anderson, was invited to participate with U.S. Secretary of Health, Michael ... , ... Salt Lake City (Vocus) November 20, 2008 -- ... Secretary of Health, Michael Leavitt, in the 2008 National Summit on ...
... "Super Dentist" award given to elite dentists in Texas. Dr. Michael ... the area of Cosmetic Dentistry. , ... Austin, TX ... was recently nominated as a "Texas Monthly Super Dentist" for ...
Cached Medicine News:Health News:Huifeng Bio-Pharmaceutical (HFGB) Reports Record Sales and Net Income 2Health News:NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan 2Health News:NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan 3Health News:Vital Images and Toshiba Renew Distribution Agreement 2Health News:Vital Images and Toshiba Renew Distribution Agreement 3Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 2Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 3Health News:MediConnect Participates in 2008 National Health Summit 2Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2
Ophthalmic Nd Yag Laser with excellent quality optics for clear image and good laser delivery. Compact and light-weight for portability....
The compact size and portability of the Epic system makes it a cost-effective solution for single or multi-office use....
A conventional blue visibility-tinted daily-wear lens, custom made for astigmats with up to -3.00 D of cylinder requiring adds of up to +2.50 D....
A soft contact lens that lets presbyopes see clearly and comfortably at all distances , without the hassles of bifocals or reading glasses. Recommended for daily wear. Also approved for extended wear...
Medicine Products: